EP0157556A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Recombinant factor VIII-C
Assignee: Meloy Laboratories Inc
•
Filing: 1985-03-22
•
Granted: —
•
Expires: 2005-03-22
Abstract
Abstract Human Factor VIII-C antihemophilic factor in essentially pure form is provided. Among the processes for its production is that of expressing DNA encoding human Factor VIII-C in a self-replicating recombinant host system. A composition for preparing human Factor VIII-C from a hererogeneous mRNA mixture containing mRNA for said protein, which composition comprises: a) means for preparing a heterogeneous ds-cDNA population complementary to a heterogeneous mRNA mixture; b) means for incorporating said ds-cDNA into a bacteriophage direct expression vector; c) a bacteriophage direct expression vector capable of incorporating said ds-cDNA population; d) means for expressing human Factor VIII-C from said ds-cDNA-containing bacteriophage; e) means for isolating and recovering human Factor VIII-C. Factor VIII-C of the invention may be administered clinically as a composition comprising also a pharmaceutically acceptable carrier, and may be used for the treatment of clotting disorders.
Inventors
- 👤 William Nash Drohan
- 👤 George A. Ricca
- 👤 Sally S.G. Lee
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 10:24
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
11 words
Human Factor VIII-C essentially free of other proteins of human origin.
Claim 2
Dependent Claim
11 words
Human Factor VIII-C essentially free of other proteins of human origin.
Claim 3
Dependent Claim
8 words
Human Factor VIII-C unaccompanied by associated native glycosylation.
Claim 4
Dependent Claim
8 words
Human Factor VIII-C unaccompanied by associated native glycosylation.
Claim 5
Dependent Claim
9 words
Human Factor VIII-C produced by a recombinant host system.
Claim 6
Dependent Claim
9 words
Human Factor VIII-C produced by a recombinant host system.
Claim 7
Dependent Claim
7 words
Human Factor VIII-C in essentially pure form.
Claim 8
Dependent Claim
7 words
Human Factor VIII-C in essentially pure form.
Claim 9
Dependent Claim
30 words
Human Factor VIII-C according to any of claims 1 to 4, comprising a polypeptide sequence extending from the N-terminus of the ordinarily first amino acid of endogeneous human Factor VIII-C.
Claim 10
Dependent Claim
26 words
A replicable expression vector capable, in a cell or cell-free self-replicating recombinant system, of expressing the human Factor VIII-C of any of claims 1 to 4.
Claim 11
Dependent Claim
14 words
A cell or cell-free self-replicating recombinant system transformed with the vector of claim 6.
Claim 12
Dependent Claim
13 words
The recombinant system of claim 7 obtained by transforming an E.coli or B.subtilis.
Claim 13
Dependent Claim
21 words
A recombinant system obtained by incorporating a cell of natural endogenous Factor VIII-C production with the expression vector of claim 6.
Claim 14
Dependent Claim
16 words
A process which comprises expressing DNA encoding human Factor VIII-C in a self-replicating recombinant host system.
Claim 15
Dependent Claim
16 words
A process which comprises expressing DNA encoding human Factor VIII-C in a self-replicating recombinant host system.
Claim 16
Dependent Claim
72 words
A process for producing human Factor VIII-C which process comprises: a) preparing a replicable expression vector capable of expressing the DNA sequence encoding human Factor VIII-C in a suitable self-replicating recombinant host system; b) transforming said host system to obtain a recombinant host system; c) maintaining said recombinant host system under condition permitting expression of said Factor VIII-C encoding DNA sequence to produce human Factor VIII-C; d) recovering said human Factor VIII-C.
Claim 17
Dependent Claim
72 words
A process for producing human Factor VIII-C which process comprises: a) preparing a replicable expression vector capable of expressing the DNA sequence encoding human Factor VIII-C in a suitable self-replicating recombinant host system; b) transforming said host system to obtain a recombinant host system; c) maintaining said recombinant host system under condition permitting expression of said Factor VIII-C encoding DNA sequence to produce human Factor VIII-C; d) recovering said human Factor VIII-C.
Claim 18
Dependent Claim
78 words
A composition for preparing human Factor VIII-C from a heterogeneous mRNA mixture containing mRNA for said protein, which composition comprises: a) means for preparing a heterogeneous ds-cDNA population complementary to a heterogeneous mRNA mixture; b) means for incorporating said ds-cDNA into a bacteriophage direct expression vector; c) a bacteriophage direct expression vector capable of incorporating said ds-cDNA population; d) means for expressing human Factor VIII-C from said ds-cDNA-containing bacteriophage; e) means for isolating and recovering human Factor VIII-C.
Claim 19
Dependent Claim
78 words
A composition for preparing human Factor VIII-C from a heterogeneous mRNA mixture containing mRNA for said protein, which composition comprises: a) means for preparing a heterogeneous ds-cDNA population complementary to a heterogeneous mRNA mixture; b) means for incorporating said ds-cDNA into a bacteriophage direct expression vector; c) a bacteriophage direct expression vector capable of incorporating said ds-cDNA population; d) means for expressing human Factor VIII-C from said ds-cDNA-containing bacteriophage; e) means for isolating and recovering human Factor VIII-C.
Claim 20
Dependent Claim
36 words
A composition comprising a therapeutically effectiv< amount of human Factor VIII-C according to any of claims 1 t 4 4, in admixture with a pharmaceutically acceptable carrier, such as, for example, one suitable for parental administrati<
Claim 21
Dependent Claim
27 words
The use of Factor VIII-C according to any of claims 1 to 4, for treatment of clotting disorders or for preparing pharmaceutical compositions useful in such treatment.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.